台股 » 個股 » 易威 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

易威

(1799)
  • 股價
    65.0
  • 漲跌
    ▼2.3
  • 漲幅
    -3.42%
  • 成交量
    434
  • 產業
    上櫃 生技醫療類股
  • 73人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
易威 (1799)籌碼相關-華南永昌-嘉義 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

華南永昌-嘉義 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/04/2200.00155.9055.50-1471-0.21%
2025/04/18159.2000.0059.3014820.21%
2025/04/09251.0000.0051.2024910.41%
2025/03/17378.3000.0077.5036160.49%
2025/03/1200.00180.0077.50-1585-0.17%
2025/03/11177.4000.0081.5015570.18%
2025/02/21169.6000.0067.8015080.20%
2025/02/2000.00565.6271.00-5497-1.01%
2025/02/19565.7200.0065.5054901.02%
2025/01/0300.00162.7062.60-1631-0.16%
2024/12/27164.0000.0063.3016970.14%
2024/12/2500.001075.1074.00-10683-1.46%
2024/12/241073.0000.0073.00106771.48%
2024/12/2000.00161.2060.40-1684-0.15%
2024/12/19163.0000.0062.7016950.14%
2024/11/2200.00172.1073.00-1672-0.15%
2024/11/1800.00269.0067.00-2676-0.30%
2024/11/15266.1000.0066.0026780.29%
2024/11/13165.0000.0064.0016520.15%
2024/11/1200.00265.2070.00-2632-0.32%
2024/11/05189.0000.0084.9016360.16%
2024/10/30994.1900.0093.8096701.34%
2024/10/29494.5000.0096.4046790.59%
2024/10/252103.0000.00100.0026870.29%
2024/10/232107.0000.00104.0027100.28%
2024/10/0800.001124.50126.00-1839-0.12%
2024/10/071115.0000.00116.5018300.12%
2024/10/0100.00298.9097.20-2787-0.25%
2024/09/190.5179.5000.00177.000.57850.06%
2024/09/180.5177.0000.00175.000.57790.06%
2024/07/230164.0000.00160.0006850.00%
2024/07/180198.0000.00196.5006110.01%
2024/07/031127.0000.00124.5014740.21%
2024/06/2800.001.7125.50130.00-1.7413-0.40%
2024/06/272112.2500.00118.5023930.51%
2024/06/1700.002104.25108.00-2353-0.57%
2024/06/0500.00199.4098.60-1315-0.32%
2024/05/3000.00191.0090.90-1320-0.31%
2024/05/29296.7500.0094.5023190.63%
2024/05/2700.001101.00100.00-1307-0.33%
2024/05/2300.00298.00100.50-2286-0.70%
2024/05/2200.00293.0091.50-2260-0.77%
2024/05/21192.2000.0093.0012500.40%
易威慢性心臟衰竭用藥獲中國藥證 明年Q1底展開銷售Anue鉅亨-2023/10/30
美新行政令強化製藥在地化 易威、泰福-KY迎來新訂單Anue鉅亨-2022/09/20
〈易威法說〉策略轉型見成效 新藥、學名藥營收比重拚達7成Anue鉅亨-2021/12/17
易威 相關文章
易威 相關影音